A blurb in the 11/14 Wall Street Journal was pretty effusive in describing Pharmacyclics' new drug (approved Wednesday) to treat mantle cell lymphoma...and went on to say it could rack up $6B in annual sales if it goes on to get approval for other types of blood cancers. Anyone have an awareness if this might eventually compete with SGEN's Adcetris?
wow. Can't get anymore vague than that answer... I'm of the humble opinion that any cancer drug approved can be made more efficient by delivering it using SGEN's ADC technology, this include PCYC which has it's usual share of side effects, toxicity, etc.